**Table S3. Two-year overall survival rates according to basal PSA levels**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | **Low pre-treatment PSA** | | | **Intermediate pre-treatment PSA** | | | **High pre-treatment PSA** | | |
|  | |  | **Overall survival**  **(n=12; 1 event)** | | | **Overall survival**  **(n=12; 4 events)** | | | **Overall survival**  **(n=13; 8 events)** | | |
|  | | | **#** | **%** | **p value** | **#** | **%** | **p value** | **#** | **%** | **p value** |
| **CTC** | negative | | 8 | 100 | 0.16 | 5 | 60 | 0.9 | 3 | 100 | 0.04 |
| positive | | 4 | 75 | 7 | 69 | 10 | 20 |
|  |  | |  |  |  |  |  |  |  |  |  |
| **AR** | negative | | 9 | 100 | 0.08 | 8 | 75 | 0.11 | 3 | 100 | 0.04 |
| positive | | 3 | 67 | 4 | 37 | 10 | 20 |
|  |  | |  |  |  |  |  |  |  |  |  |
| **AR v7** | negative | | 11 | 100 |  | 9 | 78 | 0.002 | 8 | 62 | 0.0027 |
| positive | | 1 | 0 | 3 | 0 | 5 | 0 |
|  |  | |  |  |  |  |  |  |  |  |  |
| **CTC&ARv7** | CTC negative | | 8 | 100 | 0.004 | 5 | 60 | 0.004 | 3 | 100 | 0.006 |
| CTC+/ARv70- | | 3 | 100 | 4 | 100 | 5 | 40 |
| CTC+/ARv70+ | | 1 | 0 | 3 | 0 | 5 | 0 |